Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer.
Fiche publication
Date publication
juin 2023
Journal
Biomedicines
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle, Dr BENKIRANE-JESSEL Nadia, Pr FALCOZ Pierre-Emmanuel, Dr LINDNER Véronique, Pr NOEL Georges, Dr PENCREACH Erwan, Dr IDOUX-GILLET Ysia, Dr BURCKEL Hélène, Dr FIORETTI Florence, Pr OLLAND Anne
Tous les auteurs :
Nounsi A, Seitlinger J, Ponté C, Demiselle J, Idoux-Gillet Y, Pencreach E, Beau-Faller M, Lindner V, Balloul JM, Quemeneur E, Burckel H, Noël G, Olland A, Fioretti F, Falcoz PE, Benkirane-Jessel N, Hua G
Lien Pubmed
Résumé
Radiation therapy and platinum-based chemotherapy are common treatments for lung cancer patients. Several factors are considered for the low overall survival rate of lung cancer, such as the patient's physical state and the complex heterogeneity of the tumor, which leads to resistance to the treatment. Consequently, precision medicines are needed for the patients to improve their survival and their quality of life. Until now, no patient-derived tumoroid model has been reported to predict the efficiency of radiation therapy in non-small-cell lung cancer. Using our patient-derived tumoroid model, we report that this model could be used to evaluate the efficiency of radiation therapy and cisplatin-based chemotherapy in non-small-cell lung cancer. In addition, these results can be correlated to clinical outcomes of patients, indicating that this patient-derived tumoroid model can predict the response to radiotherapy and chemotherapy in non-small-cell lung cancer.
Mots clés
chemotherapy, non-small-cell lung cancer, patient-derived tumoroid, personalized medicine, radiation therapy
Référence
Biomedicines. 2023 06 26;11(7):